DESCRIPTION

MECHANISM OF ACTION
	
Romiplostim is a thrombopoietin receptor agonist that activates intracellular transcriptional pathways via c-Mpl to increase production of platelets. 
It also works similarly to thrombopoietin (TPO), an endogenous glycoprotein hormone that regulates the production of platelets in the bone marrow.


DISTRIBUTION
Romiplostim was administered as a single intravenous (IV) dose of 0.3, 1, or 10 μg/kg or subcutaneous (SC) dose of 0.1, 0.3, 1, or 2 μg/kg.

INDICATIONS
Romiplostim injection is used to increase the number of platelets enough to lower the risk of bleeding, 
but it is not used to increase the number of platelets to a normal level. Romiplostim is in a class of medications called thrombopoietin receptor agonists.

DRUG INTERACTION 
Romiplostim is in a class of medications called thrombopoietin receptor agonists.
It works by causing the cells in the bone marrow to produce more platelets.

TOXICITY
The most common adverse reactions (≥ 5% higher patient incidence in Nplate versus placebo) are arthralgia, dizziness, insomnia, myalgia, 
pain in extremity, abdominal pain, shoulder pain, dyspepsia, and paresthesia. Headache was the most commonly reported adverse 
reaction that did not occur at ≥ 5% higher patient incidence in Nplate versus placebo.
 LD50 = 980 mg/kg.

SPECIFICATION